Frequently Asked Questions
The market is segmented based on , By Type (Primary Osteoporosis and Secondary Osteoporosis), Therapy Type (Hormone Replacement Therapy and Bisphosphonate Therapy), Treatment Type (Medication and Surgery), Mechanism of Action Type (Bisphosphonates, Selective Estrogen Receptor Modulators and Bone Resorption Inhibitors), Route of Administration Type (Oral, Intravenous, Subcutaneous and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2030.
.
The Global Osteoporosis Drug Market size was valued at USD 15576.30 USD Million in 2022.
The Global Osteoporosis Drug Market is projected to grow at a CAGR of 4.68% during the forecast period of 2023 to 2030.
The major players operating in the market include GlaxoSmithKline, F. Hoffmann La Roche, Novartis, Eli Lilly And Company, Astrazeneca, Pfizer, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Company, Sanofi, Johnson & Johnson Services, Bayer, AbbVie, Allergan, Merck & Co., Amgen, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Novo Nordisk, DAIICHI SANKYO COMPANY, Cipla .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
